Sector · MedTech
MedTech investment: capital for medical device, diagnostics and digital health companies
MedTech investors underwrite evidence: clinical, regulatory and commercial. We help medical device, diagnostics and digital health companies raising £10m and above present that evidence the way specialist and generalist investors assess it.
How investors see it
MedTech: where capital comes from, and what it needs.
A MedTech company's value is created in steps: clinical evidence, regulatory clearance, reimbursement and adoption. Investors price each step's risk, and they want to see exactly which steps are complete, which are funded by this round, and what evidence will exist when the money has been spent.
Specialist healthcare investors will interrogate the clinical and regulatory detail. Generalist growth investors and family offices will focus on the commercial evidence and the route to exit. Both expect the same discipline: claims that map to documents.
Who we work with
- Medical device companies approaching or past regulatory clearance
- Diagnostics companies scaling commercial adoption
- Digital health companies with clinical validation and revenue
- MedTech companies seeking strategic partners
Investor criteria
What investors check before they invest
The Investor Readiness Review tests each of these against your materials before an investor does.
| What investors check | What they expect to see |
|---|---|
| Clinical evidence | Study design, endpoints, results and publications, and what further evidence is needed. |
| Regulatory pathway | UKCA, CE or FDA route, classification, status and timetable. |
| Reimbursement | Coding, payment and health economic evidence in target markets. |
| Commercial traction | Sites, users, revenue, pipeline and sales cycle. |
| Intellectual property | Patents, freedom to operate and ownership. |
| Use of funds | The milestones this round reaches, and the value they create. |
Capital providers
Who invests
Specialist healthcare and life science funds
Clinical and regulatory stage companies
Growth equity
Commercial stage companies with revenue
Strategic investors
Device, diagnostics and pharmaceutical companies
Family offices
Direct investment, often with a health focus
Venture debt and private credit
Revenue generating companies
Common issues
Where raises stall
Regulatory timetable optimistic
Clearance dates without a credible plan or budget.
No reimbursement route
Clinical value without a payer.
Round funds a step, not a milestone
Capital that runs out before value is created.
Market size without adoption evidence
Addressable market quoted in place of sales evidence.
FAQ
MedTech: questions
Who invests in MedTech companies?
What do MedTech investors look for first?
Do you work with pre clinical companies?
Find out what an investor will see before approaching the market.
The Investor Readiness Review is a fixed fee assessment of your opportunity, written from the investor side of the table. You receive a scored report, the issues most likely to stop an investor, and the order in which to address them.